
Opinion|Videos|May 2, 2025
Understanding OS Through 2 Lenses: Patients and Providers in EGFRm NSCLC
Panelists discuss how health care providers and patients view survival differently, with providers being more data driven and patients focusing on living with minimal symptoms and maintaining quality of life.
Advertisement
Episodes in this series

Patient vs Health Care Provider Perspectives on Treatment Goals
Main Discussion Topics:
- Differences between how patients and providers view survival benefits
- Patient priorities regarding quality of life and symptom management
- Challenges in communicating complex efficacy data to newly diagnosed patients
Key Points for Physicians:
- Health care providers tend to be more data driven in their approach
- Patients often prioritize living with minimal symptoms and maintaining normalcy
- Newly diagnosed patients may be overwhelmed and unable to process statistical benefits
Notable Insights:
There is an emotional component to treatment decision-making that physicians must navigate, particularly when patients are still processing their diagnosis.
Clinical Significance:
Effective communication with patients requires understanding their priorities and emotional state, moving beyond statistical data to address their specific concerns and goals.
Advertisement
Related to this article

The filing is supported by phase 3 REZILIENT3 data showing a median PFS of 14.5 vs 8.5 months with zipalertinib plus chemotherapy vs chemotherapy.

A European Commission decision on belzutifan plus lenvatinib in pretreated advanced ccRCC is expected within 2 months, based on LITESPARK-011 data.

The phase 3 4WARD trial is evaluating mavorixafor for reducing infection rates and raising neutrophil counts in patients with primary chronic neutropenia.

Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.

Age, geographic location, transportation barriers, and language and communication barriers may limit patient opportunities to participate in research.

Targeting two alternate pathways at the same time led to improved outcomes in multiple preclinical models of advanced breast cancer.

Updated LEGEND cohort 1 data showed a 56% CR rate and a 24% 12-month CR rate with detalimogene in BCG-unresponsive, high-risk NMIBC with CIS.
Advertisement
Advertisement
Trending on OncLive
1
Dr Wander on the Evolving First-Line and Post–T-DXd Landscape in HER2+ Metastatic Breast Cancer
2
Dr Levy on Where Iza-Bren May Fit Following Osimertinib In EGFR-Mutated NSCLC
3
Combination Therapy Overcomes Treatment Resistance in Breast Cancer Models
4
Dr Levy on How the EGFR-Targeted Therapy Landscape Has Evolved in NSCLC
5

